<DOC>
	<DOCNO>NCT00489944</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block blood flow tumor block enzyme need cell growth . Drugs use chemotherapy , tamoxifen cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving sunitinib together tamoxifen cisplatin may kill tumor cell . PURPOSE : This phase II trial study side effect well give sunitinib together tamoxifen cisplatin work treat patient high-risk ocular melanoma .</brief_summary>
	<brief_title>Sunitinib , Tamoxifen , Cisplatin Treating Patients With High-Risk Ocular Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect adjuvant sunitinib malate , tamoxifen citrate , cisplatin disease-free survival overall survival patient high-risk ocular melanoma undergone primary therapy . - Determine toxicity regimen patient . OUTLINE : This pilot study . Patients receive oral sunitinib malate daily day 1-21 , oral tamoxifen citrate twice daily day 1-7 , cisplatin IV day 2 3 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ocular melanoma Highrisk disease , define follow : Large choroidal tumor basal diameter ≥ 16 mm and/or tumor thickness ≥ 10 mm ( T3 ) Extrascleral extension ( T4 ) Ciliary body involvement Epithelioid cell type Have undergone appropriate primary treatment ocular melanoma No measurable metastatic disease PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,200/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min AST ALT ≤ 3 time upper limit normal Pancreatic enzyme normal Thyroid function normal stable replacement therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Cardiac ejection fraction ≥ 50 % MUGA ECHO No myocardial infarction within past 6 month No congestive heart failure require medication No history pulmonary disease require supplemental oxygen No dyspnea rest No active infection No chronic underlie immunodeficiency disease No serious illness would preclude patient safety , opinion investigator No cancer within past 5 year except nonmelanoma skin cancer cervical cancer No thromboembolic disease within past 6 month PRIOR CONCURRENT THERAPY : No prior sunitinib malate , tamoxifen citrate , cisplatin No concurrent chemotherapy , radiotherapy , surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>epithelioid cell intraocular melanoma</keyword>
	<keyword>stage IIB intraocular melanoma</keyword>
	<keyword>stage IIIA intraocular melanoma</keyword>
	<keyword>stage IIIB intraocular melanoma</keyword>
	<keyword>stage IIIC intraocular melanoma</keyword>
	<keyword>stage IV intraocular melanoma</keyword>
</DOC>